Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 84, Issue 1, pp 147–153 | Cite as

Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting

  • Kazuki Tanaka
  • Naoki InuiEmail author
  • Masato Karayama
  • Hideki Yasui
  • Hironao Hozumi
  • Yuzo Suzuki
  • Kazuki Furuhashi
  • Tomoyuki Fujisawa
  • Noriyuki Enomoto
  • Yutaro Nakamura
  • Hideki Kusagaya
  • Shun Matsuura
  • Tomohiro Uto
  • Dai Hashimoto
  • Takashi Matsui
  • Kazuhiro Asada
  • Takafumi Suda
Original Article
  • 128 Downloads

Abstract

Purpose

There remains an unmet clinical need for the control of chemotherapy-induced nausea and vomiting (CINV), particularly in the prevention of nausea and the delayed phase control. We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist, a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist and dexamethasone in patients receiving carboplatin-containing chemotherapy. Olanzapine inhibits signalling via multiple neurotransmitter receptors involved in CINV.

Methods

Chemotherapy-naïve patients with lung cancer who received carboplatin-containing chemotherapy were enrolled in this phase-II study. Patients received olanzapine, aprepitant, a 5-HT3 receptor antagonist and dexamethasone. The primary endpoint was the complete response rate (no vomiting and no rescue therapy) during 120 h after administration of chemotherapy agents.

Results

Thirty-three patients received olanzapine-containing antiemetic therapy. The overall complete response rate was 93.3% (95% confidence interval, 80.4–98.3%). The frequency of nausea was 15.2% in the delayed phase and 18.2% in the overall phase. Somnolence was observed in 16 patients.

Conclusion

Adding olanzapine to antiemetic therapy with aprepitant, a 5-HT3 receptor antagonist and dexamethasone improved CINV control in patients receiving carboplatin-containing chemotherapy.

Keywords

Antiemetic Carboplatin Chemotherapy-induced nausea and vomiting Olanzapine 

Notes

Acknowledgments

This work was supported, in part, by a Grant-in-Aid from the Japan Research Foundation for Clinical Pharmacology.

Conflict of interest

All authors declare no actual or potential conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This trial is registered number UMIN000010018.

References

  1. 1.
    Roscoe JA, Morrow GR, Hickok JT, Stern RM (2000) Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manag 20:113–121CrossRefGoogle Scholar
  2. 2.
    Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482–2494CrossRefGoogle Scholar
  3. 3.
    Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356–1367CrossRefGoogle Scholar
  4. 4.
    Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478CrossRefGoogle Scholar
  5. 5.
    Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1081–1090CrossRefGoogle Scholar
  6. 6.
    Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–243CrossRefGoogle Scholar
  7. 7.
    Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 35:3240–3261CrossRefGoogle Scholar
  8. 8.
    Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M (2017) NCCN Guidelines insights: antiemesis, Version 2.2017. J Natl Compr Canc Netw 15:883–893CrossRefGoogle Scholar
  9. 9.
    Navari RM (2014) Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol 722:180–186CrossRefGoogle Scholar
  10. 10.
    Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87–96CrossRefGoogle Scholar
  11. 11.
    Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M (2016) Participants of the MECCC (2016) MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27:v119–v133CrossRefGoogle Scholar
  12. 12.
    Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198CrossRefGoogle Scholar
  13. 13.
    Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, Lam H, Milakovic M, Pasetka M, Vuong S, Chow E, DeAngelis C (2016) Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 24:2381–2392CrossRefGoogle Scholar
  14. 14.
    Navari RM, Einhorn LH, Loehrer PJ, Passik SD, Vinson J, McClean J, Chowhan N, Hanna NH, Johnson CS (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 15:1285–1291CrossRefGoogle Scholar
  15. 15.
    Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N, Yamakage M (2014) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manag 47:542–550CrossRefGoogle Scholar
  16. 16.
    Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134–142CrossRefGoogle Scholar
  17. 17.
    Ito Y, Karayama M, Inui N, Kuroishi S, Nakano H, Nakamura Y, Yokomura K, Toyoshima M, Shirai T, Masuda M, Yamada T, Yasuda K, Hayakawa H, Suda T, Chida K (2014) Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer 84:259–264CrossRefGoogle Scholar
  18. 18.
    Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, Ogawa S, Sakai K, Ichinoe A, Ueoka Y, Hasuo Y, Nishida M, Masuda S, Kato K (2016) Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 21:491–497CrossRefGoogle Scholar
  19. 19.
    Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S, Nakamura Y, Matsuda H, Yokomura K, Koshimizu N, Toyoshima M, Imokawa S, Yamada T, Shirai T, Hayakawa H, Suda T (2015) Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung cancer 90:410–416CrossRefGoogle Scholar
  20. 20.
    Jordan K, Sippel C, Schmoll HJ (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 12:1143–1150CrossRefGoogle Scholar
  21. 21.
    Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M (2015) Japan CSGo Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20:855–865CrossRefGoogle Scholar
  22. 22.
    Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, Zhang D (2009) Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:131CrossRefGoogle Scholar
  23. 23.
    Waqar SN, Mann J, Baggstrom MQ, Waqar MA, Chitneni P, Williams K, Gao F, Morgensztern D, Govindan R (2016) Delayed nausea and vomiting from carboplatin doublet chemotherapy. Acta Oncol 55:700–704CrossRefGoogle Scholar
  24. 24.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115–124CrossRefGoogle Scholar
  25. 25.
    Yoodee J, Permsuwan U, Nimworapan M (2017) Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Crit Rev Oncol Hematol 112:113–125CrossRefGoogle Scholar
  26. 26.
    Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N (2018) A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 23:382–388CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Kazuki Tanaka
    • 1
  • Naoki Inui
    • 1
    • 2
    Email author
  • Masato Karayama
    • 1
    • 3
  • Hideki Yasui
    • 1
  • Hironao Hozumi
    • 1
  • Yuzo Suzuki
    • 1
  • Kazuki Furuhashi
    • 1
  • Tomoyuki Fujisawa
    • 1
  • Noriyuki Enomoto
    • 1
  • Yutaro Nakamura
    • 1
  • Hideki Kusagaya
    • 4
  • Shun Matsuura
    • 5
  • Tomohiro Uto
    • 6
  • Dai Hashimoto
    • 7
  • Takashi Matsui
    • 8
  • Kazuhiro Asada
    • 9
  • Takafumi Suda
    • 1
  1. 1.Second Division, Department of Internal MedicineHamamatsu University School of MedicineHamamatsuJapan
  2. 2.Department of Clinical Pharmacology and TherapeuticsHamamatsu University School of MedicineHamamatsuJapan
  3. 3.Department of Clinical OncologyHamamatsu University School of MedicineHamamatsuJapan
  4. 4.Department of Respiratory MedicineShizuoka Saiseikai General HospitalShizuokaJapan
  5. 5.Department of Respiratory MedicineFujieda Municipal General HospitalFujiedaJapan
  6. 6.Department of Respiratory MedicineIwata City HospitalIwataJapan
  7. 7.Department of Respiratory MedicineSeirei Hamamatsu General HospitalHamamatsuJapan
  8. 8.Department of Respiratory MedicineSeirei Mikatahara General HospitalHamamatsuJapan
  9. 9.Department of Respiratory MedicineShizuoka General HospitalShizuokaJapan

Personalised recommendations